These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24090200)

  • 1. Development of aldose reductase inhibitors for the treatment of inflammatory disorders.
    Chatzopoulou M; Pegklidou K; Papastavrou N; Demopoulos VJ
    Expert Opin Drug Discov; 2013 Nov; 8(11):1365-80. PubMed ID: 24090200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel aldose reductase inhibitors: a patent survey (2006--present).
    Chatzopoulou M; Alexiou P; Kotsampasakou E; Demopoulos VJ
    Expert Opin Ther Pat; 2012 Nov; 22(11):1303-23. PubMed ID: 22998509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
    Maccari R; Ottanà R
    J Med Chem; 2015 Mar; 58(5):2047-67. PubMed ID: 25375908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase inhibitors: 2013-present.
    Quattrini L; La Motta C
    Expert Opin Ther Pat; 2019 Mar; 29(3):199-213. PubMed ID: 30760060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.
    Maccari R; Vitale RM; Ottanà R; Rocchiccioli M; Marrazzo A; Cardile V; Graziano AC; Amodeo P; Mura U; Del Corso A
    Eur J Med Chem; 2014 Jun; 81():1-14. PubMed ID: 24819954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.
    Kovacikova L; Prnova MS; Majekova M; Bohac A; Karasu C; Stefek M
    Molecules; 2021 May; 26(10):. PubMed ID: 34066081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening.
    Cosconati S; Marinelli L; La Motta C; Sartini S; Da Settimo F; Olson AJ; Novellino E
    J Med Chem; 2009 Sep; 52(18):5578-81. PubMed ID: 19719141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors.
    Maccari R; Ottanà R; Curinga C; Vigorita MG; Rakowitz D; Steindl T; Langer T
    Bioorg Med Chem; 2005 Apr; 13(8):2809-23. PubMed ID: 15781392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.
    Nencetti S; La Motta C; Rossello A; Sartini S; Nuti E; Ciccone L; Orlandini E
    Bioorg Med Chem; 2017 Jun; 25(12):3068-3076. PubMed ID: 28392277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors.
    Papastavrou N; Chatzopoulou M; Pegklidou K; Nicolaou I
    Bioorg Med Chem; 2013 Sep; 21(17):4951-7. PubMed ID: 23891165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.
    Papastavrou N; Chatzopoulou M; Ballekova J; Cappiello M; Moschini R; Balestri F; Patsilinakos A; Ragno R; Stefek M; Nicolaou I
    Eur J Med Chem; 2017 Apr; 130():328-335. PubMed ID: 28259841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.
    Ramunno A; Cosconati S; Sartini S; Maglio V; Angiuoli S; La Pietra V; Di Maro S; Giustiniano M; La Motta C; Da Settimo F; Marinelli L; Novellino E
    Eur J Med Chem; 2012 May; 51():216-26. PubMed ID: 22436396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure based comprehensive modelling, spatial fingerprints mapping and ADME screening of curcumin analogues as novel ALR2 inhibitors.
    Verma SK; Thareja S
    PLoS One; 2017; 12(4):e0175318. PubMed ID: 28399135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human aldose and aldehyde reductases by non-steroidal anti-inflammatory drugs.
    Ratliff DM; Martinez FJ; Vander Jagt TJ; Schimandle CM; Robinson B; Hunsaker LA; Vander Jagt DL
    Adv Exp Med Biol; 1999; 463():493-9. PubMed ID: 10352724
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors.
    Maccari R; Del Corso A; Giglio M; Moschini R; Mura U; Ottanà R
    Bioorg Med Chem Lett; 2011 Jan; 21(1):200-3. PubMed ID: 21129963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,2-Benzothiazine 1,1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase.
    Chen X; Zhang S; Yang Y; Hussain S; He M; Gui D; Ma B; Jing C; Qiao Z; Zhu C; Yu Q
    Bioorg Med Chem; 2011 Dec; 19(23):7262-9. PubMed ID: 22036211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol.
    Smeriglio A; Giofrè SV; Galati EM; Monforte MT; Cicero N; D'Angelo V; Grassi G; Circosta C
    Fitoterapia; 2018 Jun; 127():101-108. PubMed ID: 29427593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of new selective human aldose reductase inhibitors through virtual screening multiple binding pocket conformations.
    Wang L; Gu Q; Zheng X; Ye J; Liu Z; Li J; Hu X; Hagler A; Xu J
    J Chem Inf Model; 2013 Sep; 53(9):2409-22. PubMed ID: 23901876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.